Latest news with #PathosAI
Axios
15-05-2025
- Business
- Axios
Pathos AI raises $365M at $1.6B valuation
Pathos AI, a New York drug development startup, raised $365 million in a Series D at a $1.6 billion valuation. Why it matters: The round represents investors' continued interest in platforms using AI for drug development. Follow the money: The financing brings Pathos AI's total funding to around $467 million, per PitchBook data. Pathos AI did not disclose Series D investors. Backers in prior rounds included New Enterprise Associates, Revolution and Builders VC, PitchBook says. Pathos AI last raised $62 million in 2024. Catch up quick: Pathos AI was launched in 2020 by executives at Chicago-based precision medicine company Tempus, which went public last year. Tempus CEO and serial entrepreneur Eric Lefkofsky and chief operating officer Ryan Fukushima are listed as Pathos AI chairman and board member, respectively, on the company's website. Iker Huerga, a Tempus and AstraZeneca alum, joined Pathos AI as CEO earlier this month. How it works: Pathos AI says it has developed an AI-enabled platform to develop oncology drugs.
Yahoo
23-04-2025
- Business
- Yahoo
Why Tempus AI Stock Is Skyrocketing Today
Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear partnership with AstraZeneca and Pathos AI to build a multimodal foundation model for cancer drug discovery and development. Tempus AI has invested heavily over the last decade to create one of the world's largest libraries of multimodal data that can be used in developing precision medicines. The company's de-identified oncology data will be critical in building the foundation model that AstraZeneca hopes to use to accelerate its development of new cancer drugs and increase the chances of success in clinical testing for its candidates. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Tempus AI will receive $200 million in data licensing and model development fees from AstraZeneca. This amount almost exactly matches the amount of revenue the company generated in the fourth quarter of 2024. The healthcare AI company will also be able to use the multimodal foundation model it's building in collaboration with AstraZeneca and Pathos AI in its own efforts to improve patient care. This could bode well for Tempus AI's appeal to other big drugmakers seeking to harness the power of AI in their drug development processes. Risk-averse investors probably should look to other stocks to buy instead of Tempus AI. The company continues to lose money and is difficult to value. However, I think Tempus AI could be a smart pick for aggressive growth investors to buy and hold. The deal with AstraZeneca underscores the promise of its AI platform and data. Before you buy stock in Tempus Ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tempus Ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $561,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $606,106!* Now, it's worth noting Stock Advisor's total average return is 811% — a market-crushing outperformance compared to 153% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 21, 2025 Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy. Why Tempus AI Stock Is Skyrocketing Today was originally published by The Motley Fool Sign in to access your portfolio
